Johnson & Johnson on X 

Johnson & Johnson is a New Jersey healthcare company that still organizes work around a written Credo rather than a slogan of the week. On jnj.com the firm splits operating life into two named engines: Innovative Medicine, which develops and commercializes prescription therapies in oncology, immunology, neuroscience, and cardiopulmonary disease; and MedTech, which designs instruments, implants, energy, robotics, and vision products for cardiovascular, orthopaedic, surgical, and eye-care teams. The Credo, first published in 1943, ranks patients, doctors, nurses, mothers and fathers, employees, communities, and stockholders in a deliberate order. That ranking is the company’s own ethical yardstick, not a clinical claim and not a substitute for a label, a surgeon, or a regulator. The medicine side talks about science-based innovation informed by patients. Portfolio language on the corporate site names complex diseases of our time and the medicines of tomorrow. The device side talks about treating with precision in hard-to-reach anatomy, restoring structure, and making procedures less invasive. Neither sentence is medical advice. Products are prescribed, implanted, or used under professional license. Dosing, indication, contraindication, and device selection belong on approved labeling and in the operating room, not in a comment thread. Headquarters sit in New Brunswick. The listed parent trades as JNJ. Manufacturing, clinical, and commercial footprints span many countries; those maps change and belong on current filings. Official Facebook uses the jnj handle. Official X for corporate news is JNJNews. Official LinkedIn keeps the ampersand in johnson-&-johnson, matching the legal name rather than a sanitized slug. Those channels carry Credo stories, pipeline color, MedTech procedure films, and hiring notes. They are not a pharmacy, a device helpdesk, a adverse-event inbox, or a place to send medical records. Customers and counterparties include treating physicians, hospital systems, payers, researchers, suppliers, and patients who should confirm every therapy or implant with licensed clinicians. Media, investor, and privacy mail belong on the contact routes Johnson & Johnson publishes on jnj.com and investor.jnj.com. Follow the official pages for the Credo company that still runs Innovative Medicine and MedTech as two operating stories, then verify every indication, trial, and plant claim at the source. This is not medical advice. New Brunswick remains the listed home. Consumer health brands that once sat in the group have been separated; what remains on jnj.com is medicine plus devices. Hospitals, not comment threads, decide which implant or molecule is appropriate. Careers, supplier, and privacy pages sit on the same corporate domain. Treat every Credo anecdote as culture, every trial mention as a pointer to a registry, and every MedTech film as illustration rather than instruction.